March 16, 2021 6:52 AM
value
The British pharmaceutical AstraZeneca announce this Tuesday, March 16, 2021 an agreement with the United States for the shipment of 500,000 dose additional of a possible treatment against the covid with antibodies, Which, if authorized, could protect it from virus to people who cannot be vaccinated.
in a communiqué, The company explained that the pact with the Department of Health and Human Services (HHS) and the Department of Defense extends another October 2020 agreement by which the US received 100,000 initial doses of the drug AZD7442, With an option to acquire more in 2021, and promised to pay the last phase of the clinical studies.
(…)
With the 500,000 extra doses announced on March 16 and another 100,000 more agreed in parallel with Defense, AstraZeneca could supply Washington in 2021 to 700,000 dose of the drug, he notes in the note.
“The combination of antibodies with long-term effect has the potential to offer protection almost immediate to those who can not be vaccinated, both to prevent the contagion how to treat the disease in already infected patients, “said the CEO of the pharmaceutical company, Pascal Soirot.
“The support of the Government of the United States is critical to accelerating the development of AZD7442, which we believe will be a a tool important in the fight against covid-19 “, he added.
The drug, which has been designed to reduce the resistance of the most potent variants of virus, is currently evaluated in clinical trials with 9,000 volunteers in various parts of the world, the statement said.
AstraZeneca notes that the total value of agreements with the US Government for Development and the supply of AZD7442 during 2021 amounts to about $ 726 million.